Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Summary

This is a single arm open-label design study looking at Nivolumab plus Ipilimumab in patients with Advanced Neuroendocrine Tumors. Patients will be dosed Nivolumab 240mg IV over 60 minutes every 2 weeks (Q2W) and Ipilimumab 1mg/kg IV over 30 minutes every 6 weeks (Q6W). One cycle will include 3 doses of Nivolumab and 1 dose of Ipilimumab. The objective of this study is to evaluate the objective response rate of combination Nivolumab and Ipilimumab in advanced, well-differentiated neuroendocrine tumors. Durability of response, and progression free survival (PFS) will also be described.

Timeline

Start

2018-03-09

Primary completion

2021-11-24

Completion

2021-11-24

Outcome

Outcome not reported

Stopped (Business): “Loss of funding”

Drugs

Indications